Want to join the conversation?
$BIIB said the Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for marketing authorization of FLIXABI (infliximab). Previously known as SB2, FLIXABI is infliximab biosimilar candidate referencing Remicade, which was developed by Samsung Bioepis, the JV between Samsung BioLogics and $BIIB.
$BABA seems to be on a roll! But increasing its yearly sales outlook from 48% to 54% seems over-expectation from the company's part, doesn't it?
$JNJ down 2% in pre-market trading. Earnings beat expectations, but sales disappointed. Johnson is cautious on its outlook. How it will perform in the future?